Abstract:Recently, targeted degradation has emerged as a powerful therapeutic modality. Relying on "event-driven" pharmacology, proteolysis targeting chimeras (PROTACs) can degrade targets and are superior to conventional inhibitors against undruggable proteins. Unfortunately, PROTAC discovery is limited by warhead scarcity and laborious optimization campaigns. To address these shortcomings, analogous protein-based heterobifunctional degraders, known as bioPROTACs, have been developed. Compared to small-molecule PROTACs, bioPROTACs have higher success rates and are subject to fewer design constraints. However, the membrane impermeability of proteins severely restricts bioPROTAC deployment as a generalized therapeutic modality. Here, we present an engineered bioPROTAC template able to complex with cationic and ionizable lipids via electrostatic interactions for cytosolic delivery. When delivered by biocompatible lipid nanoparticles, these modified bioPROTACs can rapidly degrade intracellular proteins, exhibiting near-complete elimination (up to 95% clearance) of targets within hours of treatment. Our bioPROTAC format can degrade proteins localized to various subcellular compartments including the mitochondria, nucleus, cytosol, and membrane. Moreover, substrate specificity can be easily reprogrammed, allowing modular design and targeting of clinically-relevant proteins such as Ras, Jnk, and Erk. In summary, this work introduces an inexpensive, flexible, and scalable platform for efficient intracellular degradation of proteins that may elude chemical inhibition.

A Proximity-Triggered Strategy Toward Transferable Proteolysis Targeting Chimeras

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Palladium-Triggered Deprotection Chemistry for Protein Activation in Living Cells

Targeting Cullin-RING Ubiquitin Ligases and the Applications in PROTACs

Delivering on Cell‐Selective Protein Degradation Using Chemically Tailored PROTACs

Discovery of intracellular self-assembly protein degraders driven by tumor-specific activatable bioorthogonal reaction

Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation

Covalent PROTAC Design Method Based on a Sulfonyl Pyridone Probe

Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment

A Novel Lysosome Targeting Chimera for Targeted Protein Degradation via Split-and-Mix Strategy

Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors

Lipid-mediated intracellular delivery of recombinant bioPROTACs for the rapid degradation of undruggable proteins

Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras

Precise Modulation of Protein Degradation by Smart PROTACs

Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications

In Vivo Target Protein Degradation Induced by PROTACs Based on E3 Ligase DCAF15

Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety

Beyond Proteolysis-Targeting Chimeric Molecules: Designing Heterobifunctional Molecules Based on Functional Effectors

Conditional PROTAC: Recent Strategies for Modulating Targeted Protein Degradation

Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges

Applications of covalent chemistry in targeted protein degradation